Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
旗艦先鋒和隱喻生物技術公司宣佈與諾和諾德合作開發下一代肥胖管理療法，諾和諾德可能支付高達6億美元的預付款、開發和商業里程碑款項
Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
旗艦先鋒和隱喻生物技術公司宣佈與諾和諾德合作開發下一代肥胖管理療法，諾和諾德可能支付高達6億美元的預付款、開發和商業里程碑款項
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。